Brief: Biomea Fusion Announces FDA Clearance Of Investigational New Drug (IND) Application For BMF-219 In Type 1 Diabetes
05/10/2023 13:34
Oct 5 (Reuters) - Biomea Fusion Inc BMEA.O :
* BIOMEA FUSION ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL
NEW
DRUG (IND) APPLICATION FOR BMF-219 IN TYPE 1 DIABETES
* BIOMEA FUSION INC - FDA HAS CLEARED INITIATION OF
COVALENT-112,
A PHASE II CLINICAL TRIAL OF BMF-219 IN ADULTS WITH TYPE 1
DIABETES
* BIOMEA FUSION INC - FDA HAS CLEARED INITIATION OF
COVALENT-112,
A PHASE II CLINICAL TRIAL OF BMF-219 IN ADULTS WITH TYPE 1
DIABETES (T1D)
* BIOMEA FUSION INC - NOW ESTABLISHED A CLINICAL DEVELOPMENT
PLAN
THAT WE BELIEVE WILL FULLY EXPLORE POTENTIAL OF BMF-219 ACROSS
SPECTRUM OF DIABETES
Source text for Eikon: ID:nGNX35NwfH
Further company coverage: BMEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes